Physician profile
Kristen M Wright
NPI 1841755014
$3,735.71
in general payments reported to CMS, 2019-2025
20 companies · $977 in 2025
The $977 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $656 · 2022: $213 · 2023: $613 · 2024: $1,276 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,712.10 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,393.18 | 2021-2025 | Imfinzi, Datroway, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $558.02 | 2021-2024 | Opdivo, Pomalyst |
| Daiichi Sankyo INC. | $423.08 | 2021-2025 | Enhertu, Injectafer |
| Amgen INC. | $379.75 | 2021-2024 | Lumakras |
| Novartis Pharmaceuticals Corporation | $217.50 | 2021-2025 | |
| Abbvie INC. | $124.58 | 2024 | |
| Merck Sharp & Dohme LLC | $104.43 | 2025 | Keytruda |
| Stemline Therapeutics INC. | $101.40 | 2025 | Orserdu |
| Seagen INC. | $90.84 | 2021 | |
| Incyte Corporation | $74.99 | 2024 | |
| Array Biopharma INC | $73.41 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Genmab U.S., INC. | $53.64 | 2023-2024 | Epkinly |
| Eisai INC. | $35.40 | 2024 | |
| Tersera Therapeutics LLC | $24.56 | 2023 | Zoladex |
| Astellas Pharma US INC | $14.66 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14.27 | 2024 | Venclexta, Gazyva, Columvi |
| Lilly USA, LLC | $14.00 | 2024 | Verzenio, Jaypirca |
| Puma Biotechnology, INC. | $13.65 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.92 | 2021 | |
| Celgene Corporation | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.